05/11/11 - Sophia-Antipolis, France - MEDIAN Technologies, the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, announced that it had signed a new contract with a top-five pharma company, following on from an initial contract in 2010.The new contract covers a pilot study performed as part of a lung cancer trial. This study will investigate the use of an advanced imaging biomarker to evaluate the treatment response (tumor volume, in this case).
"This new collaboration will enable us to study the value of tumor volume as a treatment response criterion. There are several possible advantages. Firstly, the use of tumor volume could decrease variability during image interpretation. Secondly, the change over time in tumor volume may be better correlated with the patients' survival rate. Thirdly and lastly, tumor volume may show up an earlier treatment response", emphasized MEDIAN's Chairman and CEO Fredrik Brag. "Innovations in image interpretation are playing an ever more significant role in the cancer drug development process. The signature of this new contract confirms the validity of our approach", he added.
A number of cancer centers of excellence in the USA, EMEA and Australasia are involved in the study... MEDIAN Technologies' Press Release - communiqué de presse MEDIAN Technologies -
March 18, 2008 - 
